|CME/CE Released: 03/23/2012; Valid for credit through 03/23/2013|
|Recent advances in understanding the pathophysiology, diagnosis, and clinical monitoring of patients with multiple sclerosis (MS) have significantly increased the ability to detect and manage its progression. Experts continue to examine the most appropriate ways to care for patients with MS. The numerous options for the treatment of patients with MS symptoms have continued to grow and improve. Appropriate symptom management can change the course of lives and allow for more comfortable, healthier living despite significant disease. This activity will discuss advances in the symptomatic treatment and management of patients with MS in order to maximize opportunities for preserving neurological function while minimizing the possibility of side-effects and serious adverse events. This activity is a web-based interactive case focusing on patient-tailored treatment approaches and practical application of managing symptoms in patients with MS.|
|This activity is designed for physiatrists, neurologists, and allied health professionals who treat patients with MS. No prerequisites required.|
|The goal of this activity is to arm clinicians with the skills necessary to formulate effective symptom management strategies for improving overall outcomes and quality of life for patients with MS.|
|Authors and Disclosures|
|Randall T. Schapiro, MD, FAAN (Course Director) |
The Schapiro Multiple Sclerosis Advisory Group
Clinical Professor of Neurology (Ret.)
University of Minnesota
Reports receiving consulting fees and fees for non-CME services from Acorda Therapeutics, Inc, and Pfizer Inc.
June Halper, MSN, APN-C, MSCN, FAAN
Hackensack, New Jersey
Reports serving as a consultant for Acorda Therapeutics, Inc, Questcor Pharmaceuticals, Inc, and Teva Neuroscience; and serving on the speakers' bureau for Acorda Therapeutics, Inc.
Jodie K. Haselkorn, MD, MPH
Professor, Rehabilitation Medicine
Adjunct Professor, Epidemiology
University of Washington
Has disclosed no relevant financial relationships
Laurie Scudder, DNP, NP, Reviewer
Nurse Practitioner Alternatives
Has disclosed no relevant financial relationships
After participating in this activity, the participant will demonstrate the ability to:
- DISCUSS advances in the symptomatic treatment of MS.
- INTEGRATE symptom and adverse-event management into the overall patient-tailored treatment plan for patients with MS.
- FORMULATE effective management strategies for improving overall outcomes and quality of life for patients with MS.
|As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Consortium of Multiple Sclerosis Centers to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.|
|The CMSC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.|
|This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical education (ACCME) through the joint sponsorship of the Consortium of Multiple Sclerosis Centers (CMSC) and ASiM. The CMSC is accredited by the ACCME to provide continuing medical education for physicians. |
|Method to Receive Credit|
|After reviewing this online enduring activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 75% or higher.|
|Off-Label Product Discussion|
|The following faculty member has disclosed that this presentation will reference unlabeled/unapproved use of drugs or products:|
Ms Halper–Amantadine, selective serotonin reuptake inhibitors, r-modafinil, and armodafinil.
|The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This handout is produced for educational purposes only. Use of CMSC name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.|
|All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.|
|Hardware and Software Requirements|
|Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.|